S&P 500   3,332.99 (-0.48%)
DOW   27,281.97 (-0.38%)
QQQ   270.62 (-1.46%)
AAPL   442.27 (-2.93%)
MSFT   211.23 (-2.37%)
FB   267.57 (+0.86%)
GOOGL   1,489.81 (-1.01%)
AMZN   3,145.59 (-2.46%)
NVDA   442.76 (-2.35%)
CGC   16.68 (-4.79%)
BABA   248.79 (-6.36%)
TSLA   1,419.06 (-4.73%)
MU   48.25 (-0.92%)
GE   6.40 (+0.95%)
AMD   83.27 (-3.97%)
T   29.92 (+0.27%)
F   6.84 (-1.30%)
ACB   10.05 (-2.52%)
GILD   68.98 (+0.25%)
NFLX   487.92 (-4.16%)
DIS   129.16 (-1.27%)
BAC   26.02 (+2.16%)
BA   169.06 (-1.82%)
S&P 500   3,332.99 (-0.48%)
DOW   27,281.97 (-0.38%)
QQQ   270.62 (-1.46%)
AAPL   442.27 (-2.93%)
MSFT   211.23 (-2.37%)
FB   267.57 (+0.86%)
GOOGL   1,489.81 (-1.01%)
AMZN   3,145.59 (-2.46%)
NVDA   442.76 (-2.35%)
CGC   16.68 (-4.79%)
BABA   248.79 (-6.36%)
TSLA   1,419.06 (-4.73%)
MU   48.25 (-0.92%)
GE   6.40 (+0.95%)
AMD   83.27 (-3.97%)
T   29.92 (+0.27%)
F   6.84 (-1.30%)
ACB   10.05 (-2.52%)
GILD   68.98 (+0.25%)
NFLX   487.92 (-4.16%)
DIS   129.16 (-1.27%)
BAC   26.02 (+2.16%)
BA   169.06 (-1.82%)
S&P 500   3,332.99 (-0.48%)
DOW   27,281.97 (-0.38%)
QQQ   270.62 (-1.46%)
AAPL   442.27 (-2.93%)
MSFT   211.23 (-2.37%)
FB   267.57 (+0.86%)
GOOGL   1,489.81 (-1.01%)
AMZN   3,145.59 (-2.46%)
NVDA   442.76 (-2.35%)
CGC   16.68 (-4.79%)
BABA   248.79 (-6.36%)
TSLA   1,419.06 (-4.73%)
MU   48.25 (-0.92%)
GE   6.40 (+0.95%)
AMD   83.27 (-3.97%)
T   29.92 (+0.27%)
F   6.84 (-1.30%)
ACB   10.05 (-2.52%)
GILD   68.98 (+0.25%)
NFLX   487.92 (-4.16%)
DIS   129.16 (-1.27%)
BAC   26.02 (+2.16%)
BA   169.06 (-1.82%)
S&P 500   3,332.99 (-0.48%)
DOW   27,281.97 (-0.38%)
QQQ   270.62 (-1.46%)
AAPL   442.27 (-2.93%)
MSFT   211.23 (-2.37%)
FB   267.57 (+0.86%)
GOOGL   1,489.81 (-1.01%)
AMZN   3,145.59 (-2.46%)
NVDA   442.76 (-2.35%)
CGC   16.68 (-4.79%)
BABA   248.79 (-6.36%)
TSLA   1,419.06 (-4.73%)
MU   48.25 (-0.92%)
GE   6.40 (+0.95%)
AMD   83.27 (-3.97%)
T   29.92 (+0.27%)
F   6.84 (-1.30%)
ACB   10.05 (-2.52%)
GILD   68.98 (+0.25%)
NFLX   487.92 (-4.16%)
DIS   129.16 (-1.27%)
BAC   26.02 (+2.16%)
BA   169.06 (-1.82%)
Log in

NASDAQ:QTNTQuotient Stock Price, Forecast & News

$6.78
-0.30 (-4.24 %)
(As of 08/7/2020 02:21 PM ET)
Add
Compare
Today's Range
$6.78
Now: $6.78
$6.98
50-Day Range
$6.97
MA: $7.82
$8.47
52-Week Range
$2.39
Now: $6.78
$11.10
Volume16,158 shs
Average Volume670,137 shs
Market Capitalization$546.54 million
P/E RatioN/A
Dividend YieldN/A
Beta2.61
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Read More
Quotient logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.81 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QTNT
CUSIPN/A
Phone011-41-22-716-9800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.66 million
Book Value($0.07) per share

Profitability

Net Income$-102,770,000.00
Net Margins-313.16%

Miscellaneous

EmployeesN/A
Market Cap$546.54 million
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$6.78
-0.30 (-4.24 %)
(As of 08/7/2020 02:21 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QTNT News and Ratings via Email

Sign-up to receive the latest news and ratings for QTNT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Quotient (NASDAQ:QTNT) Frequently Asked Questions

How has Quotient's stock been impacted by COVID-19 (Coronavirus)?

Quotient's stock was trading at $4.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QTNT shares have increased by 47.0% and is now trading at $6.82.
View which stocks have been most impacted by Coronavirus
.

When is Quotient's next earnings date?

Quotient is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Quotient
.

How were Quotient's earnings last quarter?

Quotient Ltd (NASDAQ:QTNT) posted its earnings results on Monday, August, 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.01.
View Quotient's earnings history
.

What guidance has Quotient issued on next quarter's earnings?

Quotient updated its FY 2021 Pre-Market earnings guidance on Monday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $32-34 million, compared to the consensus revenue estimate of $36 million.

Has Quotient been receiving favorable news coverage?

Media stories about QTNT stock have been trending positive on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Quotient earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Quotient
.

Who are some of Quotient's key competitors?

What other stocks do shareholders of Quotient own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Verastem (VSTM), Gilead Sciences (GILD), Novavax (NVAX), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Ocular Therapeutix (OCUL) and Clovis Oncology (CLVS).

Who are Quotient's key executives?

Quotient's management team includes the following people:
  • Mr. Franz Walt, CEO & Director (Age 60)
  • Mr. Jeremy Stackawitz, Pres (Age 44)
  • Mr. Edward Farrell, Pres (Age 49)
  • Mr. Christopher J. Lindop, Chief Financial Officer (Age 61)
  • Mr. John Allan, Corp. Sr. VP & CTO

What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Who are Quotient's major shareholders?

Quotient's stock is owned by a variety of institutional and retail investors. Top institutional investors include Swiss National Bank (0.17%), Roubaix Capital LLC (0.14%), M&T Bank Corp (0.12%), DAVENPORT & Co LLC (0.12%), New York State Common Retirement Fund (0.07%) and SG Americas Securities LLC (0.04%). Company insiders that own Quotient stock include Edward Farrell, Frederick Hallsworth, Jeremy Stackawitz, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, Prondzynski Heino Von and Roland Boyd.
View institutional ownership trends for Quotient
.

Which institutional investors are selling Quotient stock?

QTNT stock was sold by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, Swiss National Bank, and Arizona State Retirement System. Company insiders that have sold Quotient company stock in the last year include Edward Farrell, Jeremy Stackawitz, and Roland Boyd.
View insider buying and selling activity for Quotient
.

Which institutional investors are buying Quotient stock?

QTNT stock was bought by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, New York State Common Retirement Fund, SG Americas Securities LLC, M&T Bank Corp, UBS Group AG, and Ameritas Investment Partners Inc.. Company insiders that have bought Quotient stock in the last two years include Frederick Hallsworth, Life Sciences Maste Perceptive, Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von.
View insider buying and selling activity for Quotient
.

How do I buy shares of Quotient?

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $6.82.

How big of a company is Quotient?

Quotient has a market capitalization of $549.76 million and generates $32.66 million in revenue each year. The company earns $-102,770,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis.

What is Quotient's official website?

The official website for Quotient is www.quotientbd.com.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at 011-41-22-716-9800.

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.